Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

BLTE 10.08.2024

Full Press ReleaseSEC FilingsOur BLTE Tweets

About Gravity Analytica

Recent News

  • 11.12.2024 - Belite Bio, Inc Third Quarter 2024 Financial Result Conference Call
  • 11.12.2024 - Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
  • 11.05.2024 - Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

Recent Filings

  • 01.21.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.02.2025 - 144 Report of proposed sale of securities
  • 11.12.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
PDF Version

SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Hendrik P.N. Scholl, MD, MA, Chief Medical Officer of Belite Bio, will participate in the “Ocular Drug Development” panel discussion at the Maxim Group 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 11:00 am ET.

The live panel discussion can be accessed on Maxim’s M-Vest website. For more information and to sign up, please visit:https://m-vest.com/events/healthcare-10152024.

About Belite BioBelite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us onTwitter,Instagram,LinkedIn,Facebookor visit us atwww.belitebio.com.

Media and Investor Relations Contact:Jennifer Wuir@belitebio.com

Julie Fallonbelite@argotpartners.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com